ARCHIMED to acquire a majority stake in Magellan Biologics & Consulting and ExcellGene.

ARCHIMED, a private equity healthcare specialist, agreed to acquire a majority stake in Magellan Biologics & Consulting, a provider of transient protein expression products, consulting, and small volume protein production, and ExcellGene, a company which is providing services and production in the field of recombinant biologics made with animal cells in bioreactors, such as proteins and virus vectors. Financial terms were not disclosed.